Show Summary Details
Page of

Psychopharmacological Treatment of Autism 

Psychopharmacological Treatment of Autism
Psychopharmacological Treatment of Autism

Kelly Blankenship

, Craig A. Erickson

, Kimberly A. Stigler

, David J. Posey

, and Christopher J. McDougle

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 31 July 2021

This chapter discusses pharmacologic treatment to target symptoms associated with autism and other pervasive developmental disorders. The large majority of the treatment trials have focused on one target symptom at a time. Utilizing this approach, methylphenidate and alpha 2 adrenergic agonists have been shown to be efficacious, to some extent, for inattentive and hyperactive symptoms. The antipsychotics haloperidol, risperidone, and aripiprazole have proven to be even more effective for aggression and irritability. Improvement in interfering stereotypical and repetitive behaviors with selective serotonin reuptake inhibitors has been demonstrated to be affected by development, with adults showing more improvement and less adverse events than children. Preliminary work with drugs that affect glutamate function, such as memantine, holds promise for treating aspects of social impairment.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.